Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Findings in breast cancer reported from St. Vincent's University
November 27th, 2008
" To characterize diarrhea events in patients with cancer treated with lapatinib as monotherapy or in combination with capecitabine or taxanes. Patients and methods Eleven clinical trials (phase I, II, or III) in patients with metastatic cancer were analyzed," scientists in Dublin, Ireland report. "Lapatinib was administered at doses ranging from 1,000 to 1,500 mg/day as monotherapy (n = 926) or in combination with capecitabine (n = 198) or taxanes (n = 687). Diarrhea events were characterized based on severity, time to onset, duration, required interventions, and clinical outcomes. In the pooled analysis of nine studies, diarrhea occurred in 55% of lapatinib-treated...
Source: Women's Health Weekly (2008-11-27)
|
